血脂康与辛伐他汀治疗2型糖尿病血脂异常有效性和安全性的Meta分析

Xuezhikang and simvastatin on diabetic dyslipidemia Meta-analysis of efficacy and safety

目的比较血脂康与辛伐他汀治疗2型糖尿病血脂异常的有效性和安全性。方法检索维普数据库、中国知网、万方数据库、谷歌学术、MEDLINE、EMBASE、Cochrane dadabase of systematic中关于血脂康与辛伐他汀治疗糖尿病合并血脂异常的随机对照试验(RCT),同时追索纳入文献的参考文献,检索文献从建库至2013年3月。根据Jadad系统推荐分级方法 ,对纳入研究的质量进行严格的资料提取,对符合质量标准的RCT进行Meta分析。结果纳入9篇相关文献。与辛伐他汀组对比,血脂康组三酰甘油(TG)、尿素氮(BUN)、空腹血糖(FPG)、餐后2 h血糖(2hPG)等指标的改善更显著,组间差异有统计学意义(P<0.05)。而Cr、ALT、CK、TC、LDL-C等指标改善组间差异无统计学意义(P>0.05)。结论血脂康组BUN、TG、FPG、2hPG等指标疗效显著高于辛伐他汀组,而安全性指标差异无统计学意义。

Objective To compare treatment efficacy and safety of Xuezhikang and simvastatin on diabetic dyslipidemia. Methods A meta-analysis of randomized controlled trials （RCT） was performed with database search of the CNKI, MEDLINE, EMBASE, Cochrane database of systematic reviews, Google academic, Wanfang database on Xuezhikang and simvastatin in treatment of diabetic dyslipidemia, to retrieve documents from the building of database to March 2013. Recommended classification method based on Jadad system, the quality of included studies stringent data extraction, to meet the quality standards for Meta-analysis of RCT. Results Totally 9 articles were screened, the results showed that indicators of TG, BUN, FPG, 2hPG were improved, statistically significant difference between the two groups were found （ P 〈 0.05 ）. And Cr, ALT, CK, TC, LDL-C and other indicators improved no statistically significant difference between the groups （ P 〉 0.05 ）. Conclusion This Meta-analysis show that Xuezhikang group have significantly effect in deal with index of TG, BUN, FPG, 2hPG than simvastatin group, the safety index difference was not statistically significant.